Abstract
BackgroundAim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.MethodsTotal 112 Chinese stage II-III CRC patients were respectively treated by four different chemotherapy regimens after curative operation. The TS and ERCC1 mRNA levels in primary tumor were measured by real-time RT-PCR. Kaplan–Meier curves and log-rank tests were used for DFS analysis. The Cox proportional hazards model was used for prognostic analysis.ResultsIn univariate analysis, the hazard ratio (HR) for the mRNA expression levels of TS and ERCC1 (logTS: HR = 0.820, 95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR = 1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated no significant association of DFS with the TS and ERCC1 mRNA levels. In multivariate analyses, tumor stage (IIIc: reference, P = 0.083; IIb: HR = 0.240, 95% CI = 0.080 - 0.724, P = 0.011; IIc: HR < 0.0001, P = 0.977; IIIa: HR = 0.179, 95% CI = 0.012 - 2.593, P = 0.207) was confirmed to be the independent prognostic factor for DFS. Moreover, the Kaplan-Meier DFS curves showed that TS and ERCC1 mRNA levels were not significantly associated with the DFS (TS: P = 0.264; ERCC1: P = 0.484).ConclusionThe mRNA expression of ERCC1 and TS were not applicable to predict the DFS of Chinese stage II-III CRC patients receiving 5-FU and oxaliplatin based adjuvant chemotherapy.
Highlights
Aim was to explore the association of ERCC1 and thymidylate synthase (TS) mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy
It has been reported that the gene polymorphism of ERCC1 at codon 118 was a predictive factor for the tumor response to oxaliplatin/5-FU combination chemotherapy in patients with advanced CRC [13]
We investigated the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese CRC patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy
Summary
Aim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy. It has been reported that the gene polymorphism of ERCC1 at codon 118 was a predictive factor for the tumor response to oxaliplatin/5-FU combination chemotherapy in patients with advanced CRC [13]. Thymidylate synthase (TS), as a target enzyme of 5-FU, is associated with response to 5-FU in human colorectal and gastric tumors [14,15]. It was reported that TS genotyping could be of help in predicting toxicity to 5-FU-based chemotherapy in CRC patients [16]. Little is known about the association between mRNA expression levels of ERCC1 and TS and clinical outcomes of oxaliplatin and 5-FU based adjuvant chemotherapy in Chinese people with CRC
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call